Medication Spotlight: Atectura and Enerzair

Updated: Sep 3

Novartis has come up with some interesting new products in an increasingly saturated market of respiratory inhalers for asthma. Atectura and Enerzair are once-daily inhalers which will provide more options through a Breezhaler capsule system. The Breezhaler features a capsule containing dry powder, which is intended to be punctured and inhaled (do not swallow the capsule!).

---------

The first is Atectura Breezhaler, which contains indacaterol (long acting beta agonist LABA) and mometasone (inhaled corticosteroid ICS). Atectura faces steep competition against Advair, Zenhale and Breo which feature a LABA and ICS combination. The only advantage would be the once daily dosing option, which puts it on par with Breo.

--------- The second is Enerzair Breezhaler, which contains indacaterol, mometasone and glycopyrronium (long acting muscarinic antagonist LAMA). Often, asthmatic patients may not achieve adequate control with a LABA+ICS combination, so addition of an anitcholinergic agent is an option. This is known as triple therapy, which puts it on par with Trelegy and features a similar combination.




5 views0 comments

Recent Posts

See All